NCT07392541 2026-03-23
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Tongji Hospital
Phase 1/2 Recruiting
Clinical Trials
117 trialsNCT03965234 2026-03-17
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT03734692 2026-02-12
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT06548412 2026-01-20
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT02989584 2026-01-07
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT06040970 2025-12-02
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT02393794 2025-10-06
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT06531434 2025-09-22
Establishing Best Treatment Strategy for T4 Esophageal Cancer
National Cheng-Kung University Hospital
Phase 1/2 Recruiting
NCT03298893 2025-09-19
NiCOL
Institut Curie
Phase 1/2 Completed
NCT06543576 2025-08-15
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT02432378 2025-06-19
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT06802835 2025-05-16
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06956716 2025-05-04
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Zhejiang University
Phase 1/2 Recruiting
NCT02365766 2025-03-18
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT05784012 2025-03-13
RADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 1/2 Recruiting
NCT06494943 2025-02-25
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Fudan University
Phase 1/2 Recruiting
NCT02202772 2025-02-24
CGC
Columbia University
Phase 1/2 Active not recruiting
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT04278287 2024-12-13
Chemoradiotherapy in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT03319537 2024-05-23
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT06217757 2024-05-13
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT06391190 2024-04-30
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
RenJi Hospital
Phase 1/2 Recruiting
NCT01088347 2024-04-19
Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer
University Medical Center Groningen
Phase 1/2 Completed
NCT03246750 2024-04-17
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
The Thai Lymphoma Study Group
Phase 1/2 Completed
NCT00889733 2024-03-26
OVHM-01
University Health Network, Toronto
Phase 1/2 Terminated
NCT06173986 2023-12-18
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02324543 2023-07-21
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05898256 2023-06-12
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Guangxi Medical University
Phase 1/2 Not yet recruiting
NCT03410030 2023-04-18
AA NABPLAGEM
HonorHealth Research Institute
Phase 1/2 Completed
NCT04646837 2023-03-29
Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT05441761 2022-07-01
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT01076231 2021-05-17
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT02901301 2021-04-06
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
Yonsei University
Phase 1/2 Unknown
NCT02759575 2021-03-12
A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
University of Cincinnati
Phase 1/2 Completed
NCT02992340 2021-01-14
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
ASLAN Pharmaceuticals
Phase 1/2 Terminated
NCT02604784 2020-09-17
PI-CaP
Fondazione del Piemonte per l'Oncologia
Phase 1/2 Completed
NCT00851877 2020-08-21
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT00003086 2020-07-14
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 1/2 Terminated
NCT00589056 2020-04-24
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT03706287 2020-04-06
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 1/2 Unknown
NCT01614132 2020-03-31
NOA-07
University of Regensburg
Phase 1/2 Completed
NCT02801487 2020-02-17
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Shanghai Proton and Heavy Ion Center
Phase 1/2 Terminated
NCT00565370 2020-01-18
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
Asan Medical Center
Phase 1/2 Completed
NCT01045538 2020-01-07
Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP
Asan Medical Center
Phase 1/2 Completed